6533b833fe1ef96bd129b66d
RESEARCH PRODUCT
Erythropoietic cellular analyses in luspatercept-treated lower-risk myelodysplastic syndromes (MDS): Phase 2 PACE-MDS study.
Chris RovaldiUwe PlatzbeckerPhilipp KieweMatthew L. ShermanAbderrahmane LaademMarkus P. RadsakThomas WolffCarolyn BarronJoseph G. ReynoldsJörg ChromikPeter G. LindeUlrich GermingXiaosha ZhangKatharina GötzeRajasekhar Nvs SuraganiKarin MayerAristoteles GiagounidisUta Oelschlägelsubject
Cancer ResearchOncologybusiness.industryPhase (matter)Myelodysplastic syndromesLuspaterceptCancer researchMedicineHemoglobinbusinessLigand (biochemistry)medicine.diseaseLower riskdescription
7018Background: Luspatercept (ACE-536) is a TGF-β family ligand trap promoting late-stage erythroid (E) differentiation and increases in hemoglobin. Endpoints of the ongoing, phase 2, open-label st...
year | journal | country | edition | language |
---|---|---|---|---|
2018-05-20 | Journal of Clinical Oncology |